Veerle Bossuyt - Concepedia

Author

Veerle Bossuyt

Also Known As

Bossuyt, Veerle, Tomohagu Sugie, Uday Kurkure, V Bossuyt, V. Bossuyt, Veerle Bossuyt, Veerle I Bossuyt, Veerle I. Bossuyt, Veerle Ilse Julie Bossuyt, William E. Barlow

147

Publications

5.7K

Citations

H-Index

Concepts

All Affiliations

Yale University Massachusetts General Hospital Yale Cancer Center Brigham and Women's Hospital Harvard University

About

Veerle Bossuyt is an author at Yale University specializing in medicine, oncology, and breast cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	16	1.1K
2	Health Sciences	6	6	485
3	Cell Biology	4	4	532
4	Engineering	1	1	12
5	Biomedical Engineering	1	1	12

Veerle Bossuyt

Publications

2.7K

Citations

H-Index

Page 1

	Year	Citations
PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer Hallie Wimberly, Jason R. Brown, Kurt A. Schalper, Cancer Immunology Research Breast OncologyImmunologyImmunoeditingPd-l1 Expression CorrelatesImmunotherapy	2014	384
Immunological differences between primary and metastatic breast cancer Borbála Székely, Veerle Bossuyt, Xiaofeng Li, Annals of Oncology	2018	357
A Randomized, Controlled Trial of Cavity Shave Margins in Breast Cancer Anees B. Chagpar, Brigid K. Killelea, Theodore N. Tsangaris, New England Journal of Medicine	2015	346
Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group Elena Provenzano, Veerle Bossuyt, Giuseppe Viale, Modern Pathology Surgical OncologyOncologyHealth SciencesBreast OncologyClinical Trials	2015	279
Multiplexed Quantitative Analysis of CD3, CD8, and CD20 Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer Jason R. Brown, Hallie Wimberly, Donald R. Lannin, Clinical Cancer Research	2014	165
CECR2 drives breast cancer metastasis by promoting NF-κB signaling and macrophage-mediated immune suppression Meiling Zhang, Zongzhi Liu, Keisuke Aoshima, Science Translational Medicine	2022	131
Prospective multi-institutional evaluation of pathologist assessment of PD-L1 assays for patient selection in triple negative breast cancer Emily Reisenbichler, Gang Han, Andrew M. Bellizzi, Modern Pathology Breast OncologyCancer DetectionPatient SelectionMedicinePathology	2020	129
Immune Signatures Following Single Dose Trastuzumab Predict Pathologic Response to PreoperativeTrastuzumab and Chemotherapy in HER2-Positive Early Breast Cancer Vinay Varadan, Hannah Gilmore, Kristy Miskimen, Clinical Cancer Research	2016	114
Molecular Phenotypes in Triple Negative Breast Cancer from African American Patients Suggest Targets for Therapy Robert Lindner, Catherine Sullivan, Onyinye Offor, PLoS ONE Breast OncologyMolecular PhenotypesMedicinePathologyCancer Genomics	2013	86
Response-guided neoadjuvant sacituzumab govitecan for localized triple-negative breast cancer: results from the NeoSTAR trial Laura M. Spring, Sara M. Tolaney, Geoffrey Fell, Annals of Oncology	2023	63

Page 1